Ilya Pharma has signed a 2-year extension to its immunophysiology and synthetic biology research agreement with Uppsala University, Department of Medical Cell Biology.
The new knowledge to be generated will help further de-risk and accelerate development of Ilya’s pipeline of advanced therapies based on modified lactic acid bacteria expressing human chemokines beyond acute skin wounds to diabetic wounds and inflammatory bowel disease.
Aiming to treat the first patient in 2022 or 2023
“Ilya Pharma benefits greatly in our drug development work from having access to such a resource. Native immune cell functions are best studied in vivo and when developing advanced therapies targeting specific immune cells it is important to have knowledge about the full mechanism of action and follow this in the translational- and clinical studies as well. This significantly de-risks the different programs and is how we work,” says Ilya Pharma CEO Evelina Vågesjö. “We have just completed a first in human trial with ILP100, have a phase IIa study in non-healing wounds in people with diabetes to be started in H1 2021 and are now also working on IND-enabling studies in the inflammatory bowel disease program for ILP100 and ILP101, aiming to treat the first patient in 2022 or 2023.”
Invest SEK 6 million
Under the terms of the collaboration Ilya Pharma will invest SEK 6 million to fund the research and both parties expect the work to generate new knowledge that will be presented in scientific publications.
Photo of Evelina Vågersjö: Mikael Wallerestedt
Read our full interview with Evelina Vågesjö in our current issue of Nordic Life Science magazine! Sign up for a subscription today!
